Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma

Respirology

Volumn 14, Issue 8, 2009, Pages 1156-1165

  Ohta, Ken ^a   Miyamoto, Terumasa ^b   Amagasaki, Taro ^b   Yamamoto, Manabu ^b  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

Asians; Asthma; Japanese; Omalizumab; Treatment efficacy

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; PLACEBO; THEOPHYLLINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; IMMUNOLOGY; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SORE THROAT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ACTIVITIES OF DAILY LIVING; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY FLOW RATES; FORCED EXPIRATORY VOLUME; HUMANS; JAPAN; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SLEEP; TREATMENT OUTCOME;

EID: 70350444881     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2009.01633.x     Document Type: Article

References (22)

1. Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of human reaginic antibody IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J. Immunol. 1966 97 : 75 85.
2. Platts-Mills T. The role of immunoglobulin E in allergy and asthma. Am. J. Respir. Crit. Care Med. 2001 164 (Suppl. S1 5.
3. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 2001 108 : 184 190.
4. Soler M, Matz J, Townley R, Buhl R, O'Brien J et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 2001 18 : 254 261.
5. Holgate S, Chuchalin A, Hebert J, Lotvall J, Persson G et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy 2004 34 : 632 638. (Pubitemid 38534897)
6. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004 59 : 701 708.
7. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005 60 : 309 316.
8. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. Allergy Clin. Immunol. 2005 115 : 459 465.
9. Stokes J, Casale TB. Rationale for new treatments aimed at IgE immunomodulation. Ann. Allergy Asthma Immunol. 2004 93 : 212 217.
10. Rabe K, Adachi M, Lai C, Soriano J, Vermeire P et al. Worldwide severity and control of asthma in children and adults: the global Asthma Insights and Reality surveys. J. Allergy Clin. Immunol. 2004 114 : 40 7.
11. Adachi M, Morikawa A, Ishihara K. Asthma insights and reality in Japan (AIRJ). Arerugi (Jpn. J. Allergol.) 2002 51 : 411 420 (Abstract in English).
12. Adachi M, Ohta K, Morikawa A, Nishima S, Tokunaga S et al. Changes in asthma insights and reality in Japan (AIRJ) in 2005 since 2000. Arerugi (Jpn. J. Allergol.) 2008 57 : 107 120 (Abstract in English).
13. Nakazawa T, Dobashi K. Current asthma deaths among adults in Japan. Allergol. Int. 2004 53 : 205 209.
14. Labor and Welfare of Japan. Annual population survey report from the Ministry of Health 2007 (in Japanese). Accessed 10 March 2009. Available from URL: http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai087/toukei6.html
15. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NIH Publication No 02-3659 issued January, 1995 (updated 2002).
16. Makino S, Furusho K, Miyamoto T, Ohta K. Pharmacologic Control of Asthma. Asthma Prevention and Management Guidelines. JGL, Japan, 1998. English version. Int. Arch. Allergy Immunol. 2000 121 (Suppl. 1 37 70.
17. Miyamoto T, Shida T, Tomioka T, Makino S, Kabe J et al. Report of the expert committee for reviewing the criteria for severity of bronchial asthma. Arerugi (Jpn. J. Allergol.) 1994 43 : 71 80 (in Japanese).
18. Holgate S, Bousquet J, Wenzel S, Fox H, Liu J et al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr. Med. Res. Opin. 2001 17 : 233 240.
19. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: Revised 2006 Accessed 10 March 2009. Available from URL: http://www.ginasthma.org
20. National Heart, Lung, and Blood Institute. National asthma education and prevention program. expert panel report 3: guidelines for the diagnosis and management of asthma Accessed 10 March 2009. Available from URL: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm
21. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J. Allergy Clin. Immunol. 2009 123 : 107 113.
22. Corren J, Casale TB, Lanier B, Buhl R, Holgate S et al. Safety and tolerability of omalizumab. Clin. Exp. Allergy. 2009 39 : 788 797.